Mark R. Howarth

This paper introduces Duality vaccination, a method that delivers both activating and inhibitory stimuli to shape antibody responses, using nanoparticle-based immunogens.

This paper introduces LemonCatcher and SelQueX to enable selective in-cell HDX-MS for studying protein dynamics under acidic conditions.

This paper develops mRNA-based vaccines encoding RBD quartets and shows they match or improve antibody breadth, T-cell responses, and epitope targeting compared to protein-based vaccines.

This study develops HSV-2 nanoparticles targeting both gD and gH/gL, showing that combined immunization provides robust protection through complementary mechanisms beyond neutralization.

This paper introduces NanoBondy, a covalent cell-surface modification technology for immune cells using NeissLock chemistry, demonstrating robust and specific ligation to CD45.

This paper improves the expression and stability of influenza neuraminidase by grafting antigenic loops from low-expressing variants onto high-expressing scaffolds, resulting in vaccine-effective hybrid proteins.

This paper develops a vaccine candidate using DIOSvax-H5inter nanocages that elicits cross-clade neutralising antibodies and T cell responses against diverse H5 influenza strains.

The paper introduces SpyBLI, a cell-free pipeline for rapid, accurate binding kinetics measurement from crude samples, demonstrating its applicability with nanobodies and scFvs.

This paper uses visible light to control specific protein reactions in mammalian cells, revealing early stages of cell adhesion and mechanotransduction.

This paper demonstrates a method for tunable extracellular self-assembly of multi-protein conjugates using Bacillus subtilis, enhancing enzyme resilience and enabling functional multi-protein complex formation.